Primary skeletal muscle cells were cultured as previously described (1), with minor modifications. Briefly, muscle masses from the legs of 2-4-day-old newborn mice were dissected free of skin, bones, fat and connective tissues in sterile PBS. Muscle tissues were minced in fragments and digested by 0.5% trypsinogen multiple times. Finally, cell suspensions were pooled and passed through a nylon cell strainer (80 µm mesh) to remove debris. After centrifugation (10 min at 300×g), cells were resuspended in DMEM with 10% FBS and 1% antibiotics. The suspension was adjusted to a final concentration of ~5×10 5 cells/ml in 24-well plates. The cells were maintained, differentiated and induced to insulin resistant myotubes in the same way of C2C12 cells as described above. Cells were then treated with increasing concentrations of telmisartan dissolved in DMSO (10 µM) or DMSO alone for 24 h before glucose uptake assay was performed.
Western blot analyses
Western blot analyses were performed as previously described (2) . Cells or tissues were lysed in highsalt extraction buffer (0.5 mol/L Tris, 1% NP40, 1% TritionX-100, 1 g/L sodium dodecyl sulfate, 1.5 mol/L NaCl, 0.2 mol/L EDTA, 0.01 mol/L EGTA) plus 0.2 mmol/L protease inhibitor, placed at -20°C for 20 minutes, and centrifuged at 12,000×g at 4°C for 20 minutes to remove insoluble material. Membrane protein was extracted from gastrocnemius or C2C12 myotubes according to the manufacturer's instructions (Thermo Fisher Scientific). Protein concentrations were determined using a DC protein assay kit (Bio-Rad, Hercules, CA, USA). Twenty microgram of lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and blocked with 5% non-fat milk in PBS at 37°C for 4 h. The proteins were then probed with antibodies against GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), PPARδ, PPARγ, PPARα, Akt, phospho-Akt, AS160, phospho-AS160 and Glut4 (Santa Cruz Inc, Santa Cruz, CA, USA) at a 1:1000 dilution in 0.1% Tween-20/PBS at 4°C overnight. The positive control of Glut4 antibody (SC-2243) was provided by Santa Cruz Inc (Santa Cruz, CA, USA). After incubation with appropriate secondary antibodies at 37°C for 2 h, the proteins were detected by enhanced chemiluminescence and quantified using a Gel Doc 2000 Imager (Bio-Rad, Hercules, CA, USA).
Immunofluorescence C2C12 cells were cultured and induced to insulin resistance as described above. The cells were treated with telmisartan (10 µM) or DMSO in the presence or absence of the indicated inhibitors for 24 h. After stimulating with 100 nM insulin or PBS for 30 min, the cells were fixed with 10% formalin, incubated with an anti-Glut4 antibody (Santa Cruz Inc, Santa Cruz, CA, USA) at a 1:200 dilution in PBS or with PBS alone (negative control) overnight at 4°C and then exposed to DAPI for 30 min at room temperature. Cells were subsequently incubated with fluorescein isothiocyanate (FITC)-labeled secondary antibodies for 30 min in the dark. After washing with PBS, the fluorescence images were collected using a Nikon TE2000-U inverted fluorescence microscope (Nikon Co., Tokyo, Japan) and total internal reflection microscopy (TIRFM) (Nikon Co., Tokyo, Japan) (3).
Supplementary Figure 1.
Telmisartan affects glucose uptake in insulin-resistant skeletal muscle cells. Telmisartan increased insulin-stimulated glucose uptake in palmitate-treated primary wild-type mice myotubes. And telmisartan didn't increased insulin-stimulated glucose uptake without palmitate exposure. The 
